Ironwood Pharmaceuticals | IRWD - Operating Profit


Ironwood Pharmaceuticals reported $33.22M in Operating Profit for its fiscal quarter ending in December of 2024.





Operating Profit Change Date
Acadia Pharmaceuticals USD -4.62M 22.01M Mar/2026
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
Almirall EUR 30.23M 12.8M Dec/2025
Alnylam Pharmaceuticals USD 137.59M 108.19M Mar/2026
Amarin USD -2.26M 564K Dec/2025
Ardelyx USD 5.1M 431K Dec/2025
Astellas Pharma JPY 48.57B 85.97B Mar/2026
AstraZeneca USD 7.11B 4.14B Mar/2026
Charles River Laboratories USD 119.9M 44.08M Mar/2026
Coherus Biosciences USD -39.08M 3.65M Dec/2025
Emergent BioSolutions USD -218M 69.9M Jun/2023
Esperion Therapeutics USD 85.23M 95.19M Dec/2025
Halozyme Therapeutics USD -61.77M 26.64M Mar/2026
Incyte USD 324.17M 59.7M Mar/2026
Ironwood Pharmaceuticals USD 33.22M 7.58M Dec/2024
Karyopharm Therapeutics USD -17.84M 13.44M Dec/2025
Lexicon Pharmaceuticals USD -14.78M 2.59M Dec/2025
MacroGenics USD -12.1M 30.74M Dec/2025
Moderna USD -1.39B 531M Mar/2026
Myriad Genetics USD -3M 20.3M Dec/2025
Pacira USD 4.62M 1.43M Mar/2026
PTC Therapeutics USD 45.89M 127.51M Mar/2026
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Sarepta Therapeutics USD 358.43M 768.52M Mar/2026
Takeda JPY -13.62B 182.44B Mar/2026
Ultragenyx Pharmaceutical USD -216M 102M Mar/2026
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024